A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)
- Citation:
- Am J Hematol vol 96 (12) 1595-1603
- Year:
- 2021
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Preliminary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Pharmas:
- Celgene/BMS
- Grants:
- U10CA180821, U10CA180882, UG1CA233191, UG1CA233290, UG1CA233331, UG1CA233373
- Corr. Author:
- Authors:
- Peter M. Voorhees Vera J. Suman Sascha A. Tuchman Jacob P. Laubach Hani Hassoun Yvonne A. Efebera Flora Mulkey Misty Bova-Solem Katelyn Santo Destin Carlisle Philip L. McCarthy Paul G. Richardson
- Networks:
- LAPS-MA036, LAPS-MN026, LAPS-NC007, LAPS-NY016, LAPS-NY158, NC002, OH008
- Study
- Alliance-A061202
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 1/2
- Keywords:
- Article